Welcome to our dedicated page for Omeros SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omeros Corporation (NASDAQ: OMER) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, together with AI-generated summaries to help interpret key points. Omeros is a biopharmaceutical company developing and commercializing first-in-class therapeutics for complement-mediated diseases, cancers, and addictive or compulsive disorders, and its filings offer detailed insight into these activities.
Through current reports on Form 8-K, Omeros documents material events such as the U.S. FDA approval of YARTEMLEA (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), conference call announcements, quarterly financial results, and shareholder meeting outcomes. Other 8-K filings describe the asset purchase and license agreement with Novo Nordisk for the MASP-3 inhibitor zaltenibart (OMS906), including eligibility for upfront and milestone payments and tiered royalties, as well as registered direct offerings and related purchase and placement agreements.
Investors can use this page to track how Omeros reports on capital structure and liquidity, including secured term loans, convertible senior notes, equity offerings, and royalty arrangements, all as disclosed in its SEC reports. Filings also outline grant funding for programs like OMS527 for cocaine use disorder and provide context for regulatory submissions and approvals of complement inhibitors such as YARTEMLEA and OMS1029.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important elements of lengthy filings, helping readers quickly locate information on topics such as major transactions, clinical and regulatory milestones, and shareholder votes. Real-time updates from EDGAR ensure that new OMER 8-Ks, 10-Qs, 10-Ks, and Form 4 insider transaction reports become available on this page as they are filed, while the AI layer explains complex language and structures in more accessible terms.
Omeros Corporation reports its annual results and outlines a major strategic shift toward complement-mediated diseases, oncology, and infectious disease therapies. Its lead product, YARTEMLEA (narsoplimab-wuug), became the first FDA‑approved treatment for TA‑TMA on December 23, 2025, with U.S. sales starting in January 2026.
Omeros also completed an Asset Purchase and License Agreement with Novo Nordisk, granting global rights to MASP‑3 antibody zaltenibart for an upfront $240.0 million, up to $1.8 billion in potential milestones, plus tiered royalties. The company maintains a diversified pipeline, including MASP‑2 programs OMS1029 and additional indications for narsoplimab, PDE7 program OMS527 for addiction and movement disorders, the OncotoX‑AML oncology candidate approaching IND‑enabling completion, and the T‑CAT infectious disease platform targeting multidrug‑resistant organisms.
Omeros Corporation reported a sharp turnaround in late 2025, driven by a major asset sale and its first U.S. drug approval. Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, a year earlier. For full-year 2025, net loss narrowed to $3.4 million, or $0.05 per share, from a $156.8 million loss in 2024.
Results reflected a $237.6 million net gain from the zaltenibart transaction with Novo Nordisk and a $136.0 million non-cash loss from marking embedded derivatives on the company’s 2029 Notes and Term Loan. Excluding this non-cash item, non-GAAP adjusted net income was $222.5 million, or $3.14 per share, for the quarter and $133.4 million, or $2.10 per share, for the year.
At December 31, 2025, Omeros held $171.8 million in cash and short-term investments and had $87.9 million in aggregate principal debt, down from $164.9 million a year earlier after using Novo Nordisk proceeds to repay its senior secured term loan and 2026 convertible notes. The company also achieved FDA approval and U.S. launch of YARTEMLEA for TA-TMA, began commercial sales in January 2026, and highlighted progress across its oncology, PDE7, and T-CAT infectious disease programs.
Omeros Corp ownership disclosure: The Vanguard Group filed an amended Schedule 13G/A describing an internal realignment that disaggregates certain subsidiaries and business divisions. The filing states amount beneficially owned: 0 and percent of class: 0% following the realignment, with no sole or shared voting or dispositive power reported. The filing explains that subsidiaries will report separately under SEC Release No. 34-39538.
Omeros Corporation’s Chairman, CEO & President Gregory A. Demopulos reported the exercise of stock options for 400,000 shares of common stock on February 18, 2026. The options, which vested over 48 monthly installments starting April 1, 2015, were exercised via a derivative conversion.
In connection with this exercise, 357,678 shares of common stock were withheld by Omeros to cover the exercise price and related tax liability, based on the closing stock price on February 17, 2026. The company states these withheld shares remained in its treasury and the transaction did not involve any open‑market sale.
Following the transactions, Demopulos directly owned 1,469,308 shares of common stock. Additional indirect holdings include 300,000 shares in each of two irrevocable gift trusts for his minor children and 123,945 shares held by his spouse, for which he disclaims beneficial ownership except to any pecuniary interest.
The Vanguard Group filed a Schedule 13G reporting beneficial ownership of 4,013,315 shares of Omeros Corp common stock, representing 5.66% of the class as of the event date. This makes Vanguard a significant institutional holder in the company.
Vanguard reports no sole voting or dispositive power. It has shared voting power over 509,158 shares and shared dispositive power over all 4,013,315 shares. Vanguard states the shares are held in the ordinary course of business, not to change or influence control of Omeros.
Omeros Corp executive David J. Borges, VP, Finance & CAO, reported option exercises and share sales in January 2026. On January 12, 2026, he sold 30,000 shares of common stock at a weighted average price of $12.72, leaving no common shares directly owned after that sale.
On January 13, 2026, Borges exercised a stock option for 30,000 shares at an exercise price of $3.06 per share and acquired those shares, then sold 30,000 shares the same day at a weighted average price of $12.3105, again ending with 0 common shares directly held. He continues to hold 65,000 stock options following these transactions.
The option referenced vests in 48 equal monthly installments starting on April 1, 2024. The filing notes that Borges has completed all currently planned sales of Omeros common stock.
A holder of OMER common stock has filed a notice of proposed sale of 30,000 shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an indicated aggregate market value of 369,315.00, and there were 70,900,459 shares outstanding at the time of the notice.
The 30,000 shares to be sold were acquired on 01/13/2026 by exercising stock options under a registered plan, paid for in cash on the same date. The filing also shows that David J Borges sold an additional 30,000 common shares on 01/12/2026 for gross proceeds of 381,600.00 during the prior three months.
A shareholder of OMER has filed a notice of proposed sales of common stock under Rule 144. The filing indicates an intention to sell 30,000 common shares through Morgan Stanley Smith Barney LLC on or about 01/12/2026 on the NASDAQ, with an indicated aggregate market value of $381,600.00. The shares relate to prior open market purchases of 10,000 shares on 05/15/2022 and 20,000 shares on 11/14/2023, both paid in cash. The document notes that the person signing represents they are not aware of undisclosed material adverse information about the issuer.
Omeros Corporation disclosed preliminary year-end liquidity figures following an investor call. The company reported that at December 31, 2025, it had approximately $171.5 million in cash and short-term investments available for operations. This amount is described as preliminary and unaudited and may change after the company completes its customary financial closing procedures and adjustments.
The disclosure is provided under a current report and is specifically designated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions and will not automatically be incorporated into other securities filings.
Omeros Corporation reported that the U.S. Food and Drug Administration has approved YARTEMLEA® (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a serious and often fatal complication of stem-cell transplantation linked to activation of the lectin pathway of complement. The company issued a revised press release on December 24, 2025 to update the date of its YARTEMLEA approval-related conference call and to add supplemental information about the experts quoted, with no other changes to the release.